# Technology News

[![Update README with Latest Tech News](https://github.com/tcdtist/daily-tech-digest/actions/workflows/main.yml/badge.svg)](https://github.com/tcdtist/daily-tech-digest/actions/workflows/main.yml)

## NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistanceThe Phase 1 ragistomig study achieved its objective, as the new Q6W extended dosing interval produced strong anti-tumor efficacy in PD-L1-non-responders, with an improved safety profileThe interim results, including immunological data on CD8+ cell proliferation and memory T-cell activation, are expected to be presented in a poster session at ESMO-IO on December 10, 2025 ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that new data from the expanded Phase 1 dosing study for ragistomig, a 4-1BB X PD-L1 bispecific antibody, will be presented in a poster at the European Society for Medical Oncology - Immuno-Oncology Congress 2025 (ESMO-IO 2025) by co-developer ABL Bio. The poster (Abstract #688) will be presented by Gerald Falchook, MD, Director of the Sarah Cannon Research Institute (SCRI) at HealthONE Denver, on Wednesday, December 10th at 5:30 PM GMT.
[Read more](https://www.manilatimes.net/2025/12/04/tmt-newswire/globenewswire/novabridge-announces-presentation-of-ragistomig-expanded-phase-1-data-at-esmo-io/2236692)



Last updated: 2025-12-04 12:55:12